1. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
- Author
-
Lobo, Suzana Margareth, primary, Plantefève, Gaétan, additional, Nair, Girish, additional, Joaquim Cavalcante, Adilson, additional, Franzin de Moraes, Nara, additional, Nunes, Estevao, additional, Barnum, Otis, additional, Berdun Stadnik, Claudio Marcel, additional, Lima, Maria Patelli, additional, Lins, Muriel, additional, Hajjar, Ludhmila Abrahao, additional, Lipinski, Christopher, additional, Islam, Shaheen, additional, Ramos, Fabiano, additional, Simon, Tiago, additional, Martinot, Jean-Benoît, additional, Guimard, Thomas, additional, Desclaux, Arnaud, additional, Lioger, Bertrand, additional, Neuenschwander, Fernando Carvalho, additional, DeSouza Paolino, Bruno, additional, Amin, Alpesh, additional, Acosta, Samuel Amil, additional, Dilling, Daniel Forde, additional, Cartagena, Edgardo, additional, Snyder, Brian, additional, Devaud, Edouard, additional, Barreto Berselli Marinho, Ana Karolina, additional, Tanni, Suzana, additional, Milhomem Beato, Patricia Medeiros, additional, De Wit, Stephan, additional, Selvan, Vani, additional, Gray, Jeffrey, additional, Fernandez, Ricardo, additional, Pourcher, Valérie, additional, Maddox, Lee, additional, Kay, Richard, additional, Azbekyan, Anait, additional, Chabane, Mounia, additional, Tourette, Cendrine, additional, Esmeraldino, Luis Everton, additional, Dilda, Pierre J., additional, Lafont, René, additional, Mariani, Jean, additional, Camelo, Serge, additional, Rabut, Sandrine, additional, Agus, Samuel, additional, Veillet, Stanislas, additional, Dioh, Waly, additional, van Maanen, Rob, additional, and Morelot-Panzini, Capucine, additional
- Published
- 2024
- Full Text
- View/download PDF